1. Report Industry Investment Rating - No relevant content provided 2. Core View of the Report - The continuous improvement of the stock market since 2026 is the result of the joint action of four factors: the resonance of the technology cycle, the release of policy dividends, the improvement of economic recovery, and the return of overseas funds. Currently, the market has gradually shifted from being dominated by valuation expansion to a new stage driven by earnings. It is expected that in 2026, supply - side reforms will continue, pushing up the prices of bulk commodities and driving up resource - based stocks. Under the strategic guidance of the "15th Five - Year Plan", with the continuous release of the effects of various policies, the further strengthening of economic recovery momentum, and the continuous progress of overseas funds allocating Chinese assets, the stock market is expected to continue its upward trend in a volatile manner [2] 3. Summary by Relevant Catalogs 3.1 Stock Index Futures Market - **IF Contracts**: The previous day's closing prices of IF contracts for the current month, next month, next quarter, and the quarter after next were 4789.40, 4780.60, 4774.00, and 4735.20 respectively, with increases of 31.80, 34.40, 34.00, and 39.60. The trading volumes were 38339.00, 9202.00, 89188.00, and 19363.00, and the changes in open interest were - 2278.00, 2742.00, 249.00, and 2042.00 respectively [1] - **IH Contracts**: The previous day's closing prices of IH contracts for the current month, next month, next quarter, and the quarter after next were 3141.80, 3139.40, 3140.20, and 3133.40 respectively, with increases of 10.80, 9.40, 9.20, and 12.20. The trading volumes were 12654.00, 2301.00, 33564.00, and 5526.00, and the changes in open interest were - 1266.00, 179.00, - 303.00, and 292.00 respectively [1] - **IC Contracts**: The previous day's closing prices of IC contracts for the current month, next month, next quarter, and the quarter after next were 8273.80, 8258.20, 8236.60, and 8083.40 respectively, with increases of 206.20, 224.20, 231.40, and 248.80. The trading volumes were 44368.00, 12805.00, 114590.00, and 31591.00, and the changes in open interest were - 6659.00, 2512.00, - 6868.00, and 3355.00 respectively [1] - **IM Contracts**: The previous day's closing prices of IM contracts for the current month, next month, next quarter, and the quarter after next were 8395.20, 8354.40, 8311.40, and 8104.80 respectively, with increases of 263.00, 285.20, 300.40, and 317.20. The trading volumes were 63127.00, 19752.00, 172951.00, and 42733.00, and the changes in open interest were - 4313.00, 5319.00, 4629.00, and 4004.00 respectively [1] - **Inter - month Spreads**: The current inter - month spreads of IF, IH, IC, and IM contracts were - 8.80, - 2.40, - 15.60, and - 40.80 respectively, compared to the previous values of - 11.60, - 0.20, - 30.00, and - 61.40 [1] 3.2 Stock Index Spot Market - **Index Performance**: The previous day's values of the CSI 300, SSE 50, CSI 500, and CSI 1000 indices were 4789.92, 3143.74, 8249.13, and 8357.01 respectively, with increases of 0.65%, 0.30%, 2.39%, and 2.80% [1] - **Industry Performance**: Among different industries, the energy industry decreased by 0.97%, while the raw materials, industrial, and optional consumption industries increased by 0.21%, 0.19%, and - 0.39% respectively. The main consumption, medical and health, real - estate finance, and information technology industries increased by 0.49%, 0.49%, 0.17%, and 1.91% respectively. The telecommunications and public utilities industries increased by 2.57% and 0.52% respectively [1] 3.3 Futures - Spot Basis - **IF Contracts**: The basis of IF contracts for the current month, next month, next quarter, and the quarter after next against the CSI 300 index were - 0.52, - 9.32, - 15.92, and - 54.72 respectively, compared to the previous values of 5.88, - 5.72, - 15.12, and - 56.92 [1] - **IH Contracts**: The basis of IH contracts for the current month, next month, next quarter, and the quarter after next against the SSE 50 index were - 1.94, - 4.34, - 3.54, and - 10.34 respectively, compared to the previous values of - 1.32, - 1.52, 0.48, and - 11.12 [1] - **IC Contracts**: The basis of IC contracts for the current month, next month, next quarter, and the quarter after next against the CSI 500 index were 24.67, 9.07, - 12.53, and - 165.73 respectively, compared to the previous values of 31.51, 1.51, - 18.89, and - 191.09 [1] - **IM Contracts**: The basis of IM contracts for the current month, next month, next quarter, and the quarter after next against the CSI 1000 index were 38.19, - 2.61, - 45.61, and - 252.21 respectively, compared to the previous values of 31.02, - 30.38, - 80.78, and - 304.98 [1] 3.4 Other Domestic and Overseas Indexes - **Domestic Indexes**: The previous day's values of the Shanghai Composite Index, Shenzhen Component Index, Small and Medium - sized Board Index, and ChiNext Index were 4165.29, 14366.91, 8811.04, and 3388.34 respectively, with increases of 1.09%, 1.75%, 1.60%, and 1.82% [1] - **Overseas Indexes**: The previous day's values of the Hang Seng Index, Nikkei 225, S&P 500, and DAX Index were 26608.48, 51939.89, 6977.27, and 25376.43 respectively, with increases of 1.44%, 1.61%, 0.16%, and 0.45% [1] 3.5 Macro Information - **US Fed Investigation**: The US Department of Justice has launched a criminal investigation into Fed Chairman Powell regarding the renovation of the Fed headquarters. This has led to concerns about the Fed's independence, and the "Sell US" trade has resurfaced, with safe - haven demand pushing up the prices of spot gold and silver [2] - **Chinese Government Investment Fund**: Four Chinese government departments have jointly issued a work plan to clarify the layout and investment direction of government investment funds, aiming to support major strategies, key areas, and weak links where the market cannot effectively allocate resources [2] - **China - EU Electric Vehicle Case**: The EU will issue a guidance document on price - commitment applications, and China's Chamber of Commerce for Import and Export of Machinery and Electronic Products will encourage and support relevant enterprises to apply for price commitments [2] - **Chinese Industrial Policy**: The Minister of Industry and Information Technology stated that during the "15th Five - Year Plan" period, China will implement actions to revitalize traditional industries, promote the "AI +" initiative, and develop emerging industries [2] 3.6 Industry Information - **Storage Chip Industry**: The global storage chip industry chain is in a new round of price - increase cycle, and leading packaging and testing manufacturers have raised their quotes by up to 30% [2] - **Real Estate Industry**: Tianjin's housing construction department will manage the sales prices of new commercial housing to prevent excessive price drops [2] - **Space Industry**: The Mars sample return mission jointly carried out by NASA and ESA has been cancelled due to budget cuts, while China's Mars sample return plan is expected to be implemented in 2031 [2] - **Power Industry**: The generator rotor of a 630℃ power unit in a national power demonstration project has been successfully installed, with the power generation thermal efficiency of the two 630℃ ultra - supercritical double - reheat coal - fired generating units exceeding 50% [2]

Industry Overview - The food and beverage industry index increased by 2.12%, underperforming the Shanghai and Shenzhen 300 index by 0.66 percentage points, with most sub-sectors, except for meat products and dairy, showing gains [3] - The overall valuation of the food and beverage industry is at a low level, with a PE ratio of 21X, ranking 23rd among the Shenwan primary industries [3] - Inflation data indicates a rise in CPI, with a month-on-month increase of 0.2% and a year-on-year increase of 0.8%, driven by increased consumer demand and rising food prices [4][5][6] Investment Recommendations - The food and beverage industry is currently rated as a "buy," with a focus on three main investment lines: stable demand industry leaders, companies innovating in new products and channels, and undervalued segments with high growth potential [7] - Specific companies to watch include Guizhou Moutai, Miaokelando, Andeli, Shanxi Fenjiu, Yanjing Beer, and Salted Fish Shop [7] Medical Services Sector - The pharmaceutical and biological sector saw a rise of 7.81%, outperforming the Shanghai and Shenzhen 300 index by 5.03 percentage points, with the medical services sub-sector increasing by 12.34% [10] - The commercialization of brain-computer interfaces (BCI) is expected to accelerate, supported by government policies and technological breakthroughs, indicating a potential new growth area in the medical field [11] - The medical services sector is rated as a "buy," with a focus on high-growth companies in the pharmaceutical outsourcing and consumer medical fields, such as WuXi AppTec and Aier Eye Hospital [13]

09:25 A股开盘丨三大指数集体高开 沪指高开0.11%，深成指高开0.21%，创业板指高开0.07%，科创综指低开0.12%。 | 代码 | 名称 | 两日图 | 现价 | 涨跌 | 涨跌幅 | | --- | --- | --- | --- | --- | --- | | 000001 | 上证指数 | W/ | 4169.70 | 4.42 | 0.11% | | 399001 | 深证成指 | NA | 14397.68 | 30.78 | 0.21% | | 399006 | 创业板指 | 3 | 3390.69 | 2.35 | 0.07% | | 000680 | 科创综指 | No | 1853.18 | -2.21 | -0.12% | 2026.01.13 本文字数：596，阅读时长大约1分钟 作者 |一财阿驴 09:30AI应用方向延续强势，引力传媒7天6板，易点天下、卓易信息、迪安诊断、利欧股份、省广集团 均3连板。 恒生指数高开1.32%，恒生科技指数涨1.93%。科网股全线走强，阿里巴巴、阿里健康涨近5%，小鹏汽 车涨逾4%，金蝶国际、比亚迪股份涨逾3%。兆易创新H股上市高开45 ...

Core Viewpoint - The Ministry of Civil Affairs and seven other departments have introduced measures to foster the elderly care service sector and promote the silver economy through technological advancements and product development [1] Group 1: Encouragement of Technological Development - The measures encourage breakthroughs in elderly care technology and product research and development [1] - There is a focus on the digital transformation of elderly care services, utilizing big data, cloud computing, artificial intelligence, and Beidou technology for health monitoring and personalized services [1] Group 2: Support for Robotics and Cross-Industry Collaboration - The initiative promotes the development of elderly care robots to meet the daily care, emotional support, and social needs of the elderly [1] - It aims to facilitate collaboration and technological integration across industries, including robotics, medical rehabilitation, and smart home technologies [1] Group 3: Product Development and Application - The measures advocate for the acceleration of research and development in embodied intelligence technology, new materials, genetic technology, and rehabilitation aids [1] - There is an emphasis on exploring advanced technologies such as brain-machine interfaces, exoskeleton robots, and muscle exosuits to support elderly individuals with declining physical functions [1] Group 4: Enhancing User Experience - Support is provided for the integration of smart elderly care devices and rehabilitation robots into care institutions, enhancing user experience through shared services, equipment leasing, and pilot testing [1] - The initiative encourages collaboration between various elderly care institutions and smart product developers to create demonstration and experience areas for elderly-friendly technology [1]

天眼查专业版工商信息数据显示，截至目前我国现存在业、存续状态的人工智能相关企业超500万家。其中，2025年新增注册相关企业超120.2万余家，从企 业注册数量趋势来看，近五年间，人工智能相关企业的注册数量呈现出逐年增长的态势，并在2025年达到顶峰。从区域分布来看，广东省人工智能相关企业 数量位居首位，以超77.2万余家相关企业数量占全国总数的15.45%。排在其后的是北京市、江苏省、山东省和浙江省，相关企业数量分别为超40.1万余家、 38.5万余家、32.8万余家和30.6万余家。 鉴于脑机接口技术涉及数据安全、伦理及高度专业的合规要求，合作前的深度尽调不可或缺。天眼风险功能支持对目标企业进行系统性扫描，高效识别其是 否存在经营异常、法律诉讼等历史记录，帮助机构提前预警并规避技术合作、股权投资及数据治理中的潜在风险。在涉及投融资、战略入股或产业整合时， 股东信息查询与股权全景穿透图可清晰揭示企业背后的资本脉络、控制链条与关联网络，并精准定位最终受益人，为理解其真实的资本背景、战略协同性与 长期稳定性提供核心依据。 近日，工业和信息化部等八部门印发《"人工智能+制造"专项行动实施意见》，旨在加快人工智能与 ...

Core Insights - The development of brain-computer interfaces (BCIs) is expected to be a core technology for future applications, particularly in the context of ultra-low power, high-performance computing chips that can integrate with brain-like intelligence [1][2] Group 1: Industry Development and Challenges - The BCI industry is projected to face significant challenges, including the need for technological and industrial integration to avoid homogenized competition and to accelerate original innovation [3] - There is a notable demand for BCIs driven by the treatment of difficult-to-treat diseases such as cognitive disorders and neurological injuries, as well as common issues like depression and insomnia, indicating a potential trillion-dollar market in consumer healthcare [2][3] - The current BCI companies are primarily starting from electrode and algorithm development, necessitating a transition to system and product applications [2] Group 2: Research and Innovation - The integration of optogenetics and artificial intelligence is paving the way for programming neural clusters and circuits, which could lead to more precise treatments for brain diseases [2] - Fudan University is actively building a comprehensive innovation chain in medical applications, having invested over 1 billion yuan in major projects related to BCIs and brain science [5][6] - The establishment of the Shanghai Zuqin Innovation Transformation Research Institute aims to facilitate the high-quality transformation and industrialization of scientific achievements, focusing on future industries like quantum technology and BCIs [7] Group 3: Funding and Investment - Fudan Innovation Fund plans to invest approximately 8 billion yuan over the next three years to support the transformation and industrialization of cutting-edge technologies and future industries [7] - Recent significant investments in the BCI sector include a 2 billion yuan financing round for Strong Brain Technology, marking it as the second-largest financing in the world outside of Neuralink [5]

每经AI快讯，有投资者在投资者互动平台提问：公司持有哪些脑机接口公司？ 三七互娱（002555.SZ）1月12日在投资者互动平台表示，公司目前已投资的脑机接口公司包括华南脑控 及强脑科技，分别投资2000万元人民币及2000万美元。 （文章来源：每日经济新闻） ...

Core Insights - The report emphasizes the importance of long-term investment strategies and the need for a conducive regulatory environment to attract more long-term capital into the market [5] - It highlights the expected increase in storage prices by 40%-50% in Q1 2026, indicating potential investment opportunities in related companies [6] - The report notes a surge in approvals for innovative domestic drugs, presenting a favorable environment for pharmaceutical companies [6] Domestic Financial Market - The Shanghai Composite Index closed at 4165.29, up by 1.09%, while the Shenzhen Component Index rose by 1.75% to 14366.91 [3] - The ChiNext Index increased by 1.82%, closing at 3388.34, reflecting a positive market sentiment [3] Macro News Summary - The China Securities Regulatory Commission (CSRC) aims to enhance the institutional environment for long-term investments [5] - The National Bureau of Statistics is exploring innovative registration systems to unlock data value [5] - The Ministry of Industry and Information Technology is focusing on advanced technologies such as quantum technology and 6G during the 14th Five-Year Plan [5] Industry Developments - Storage prices are projected to rise significantly, with companies like Lanke Technology and Changdian Technology being highlighted as potential beneficiaries [6] - Meta's investment in a nuclear power plant for AI power supply suggests growth in the nuclear fusion industry, with companies like Lianchuang Optoelectronics and China Nuclear Engineering being relevant [6] - The approval of innovative drugs is expected to create opportunities for companies like BeiGene and Heng Rui Medicine [6] Company Focus - Kexiang Co., Ltd. is noted for its PCB products used in aerospace and storage devices [7] - East China Pharmaceutical's subsidiary has developed a breakthrough treatment for severe hypertriglyceridemia [7] - Yinkang Life has established a comprehensive management solution for Parkinson's disease treatment [7] - Shengyang Technology is recognized as the sole provider of DVB-NIP software and hardware, gaining recognition from a leading European satellite operator [7] Market Review and Outlook - The market experienced a strong upward trend with all major indices closing higher, and trading volume exceeding 3.6 trillion yuan [8] - Sectors such as software services, internet, and aerospace saw significant gains, driven by AI-related catalysts [8] - Precious metals like gold and silver reached historical highs, indicating a shift in investor sentiment [8] - The report suggests a continued positive outlook for industrial resource sectors and low-positioned stocks benefiting from policy changes [9]

Group 1: Industry Developments - The People's Bank of China has launched the "Action Plan" for strengthening the digital RMB management service system, marking the entry into the 2.0 era of digital RMB [1] - The Ministry of Industry and Information Technology plans to implement actions for traditional industry renewal and the development of emerging industries, focusing on breakthroughs in quantum technology, humanoid robots, brain-machine interfaces, deep-sea polar technology, and 6G [2] - The commercial aerospace sector achieved a milestone with the successful suborbital flight test of the "Lihong No. 1" vehicle, marking the first domestic recovery test of a suborbital capsule [7] Group 2: Company News - Guizhou Moutai plans to adjust the factory prices of several products, including a reduction of the "Moutai Boutique Wine" price from 2969 yuan to 1859 yuan [10] - WuXi AppTec expects to achieve approximately 45.456 billion yuan in revenue for 2025, a year-on-year increase of about 15.84%, with net profit expected to reach approximately 19.151 billion yuan, a growth of about 102.65% [10] - TSMC anticipates a net profit of 475.2 billion New Taiwan dollars (approximately 15.02 billion USD) in Q4 2025, a 27% year-on-year increase, driven by rising global AI infrastructure demand [12]

Summary of the Conference Call for Botao Bio Company Overview - **Company**: Botao Bio - **Investment**: Strategic investment in Qingshi Yongjun, focusing on brain-computer interface (BCI) technology for treatment of treatment-resistant depression (TRD) [2][3] Key Industry Insights - **Market Potential**: Approximately 20 million patients globally suffer from treatment-resistant major depression, indicating a significant market opportunity [2][8] - **Current Treatment Landscape**: Existing treatments for TRD are largely ineffective, creating a gap for innovative solutions like those being developed by Qingshi Yongjun [8][9] Core Points and Arguments - **Strategic Investment**: Botao Bio's investment in Qingshi Yongjun is not purely financial; it aims to enhance R&D capabilities in the BCI field [2][3] - **Clinical Trials**: Initial clinical trial data shows promising results, with one patient reportedly cured after one week of treatment [2][6] - **Future Clinical Trials**: A formal clinical trial involving 100 patients is expected to start in the second half of 2026, pending successful preliminary results [7] - **Regulatory Pathway**: Botao Bio plans to obtain Class III medical device registration by around 2029, with a focus on promoting the product through top-tier hospitals [2][10] Financial Aspects - **Projected Costs**: Estimated treatment costs are around 500,000 CNY, with a product factory price of approximately 200,000 CNY [11] - **Funding Requirements**: Anticipated clinical and registration costs are over 100 million CNY, with plans for further investment in Qingshi Yongjun [12] Collaboration and Market Strategy - **Synergy with Qingshi Yongjun**: Both entities share a unified core team and are integrated with Zhejiang University’s research institute, enhancing their collaborative potential [4][5] - **Market Expansion Plans**: Botao Bio aims to expand into international markets, including obtaining FDA certification for the U.S. market [10][11] Additional Insights - **Impact of External Factors**: The suspension of U.S.-China tariffs and currency fluctuations have positively influenced Botao Bio's U.S. business outlook [4][18] - **IVD Industry Outlook**: The IVD industry is expected to show slight improvement in 2026, although competition remains fierce [21] - **Microfluidics Development**: Botao Bio is investing in microfluidics technology, targeting revenue goals of 500 million to 1 billion USD in the coming years [20] Conclusion Botao Bio is strategically positioning itself in the burgeoning field of brain-computer interfaces, particularly for treatment-resistant depression, with a robust plan for clinical trials and market expansion. The company is leveraging its financial resources and collaborative partnerships to navigate regulatory pathways and capitalize on significant market opportunities.